» Articles » PMID: 15800944

Herceptin-induced Inhibition of ErbB2 Signaling Involves Reduced Phosphorylation of Akt but Not Endocytic Down-regulation of ErbB2

Overview
Journal Int J Cancer
Specialty Oncology
Date 2005 Apr 1
PMID 15800944
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

The anti-proliferative effect of the ErbB2 specific antibody Herceptin in cells overexpressing ErbB2 has previously been explained by endocytic downregulation of ErbB2. However, in the following, we demonstrate that Herceptin inhibited proliferation of ErbB2 overexpressing cells without downregulating ErbB2. Herceptin did also not induce endocytosis of ErbB2. Herceptin was found to blunt proliferation of SKBr3 cells overexpressing EGFR, ErbB2, and ErbB3 and expressing functional PTEN, probably by recruiting PTEN to the plasma membrane. Akt was found to be constitutively phosphorylated both in SKBr3 cells overexpressing EGFR, ErbB2 and ErbB3, and in SKOv3 cells, overexpressing EGFR and ErbB2. However, phosphorylation of Akt was inhibited by Herceptin only in SKBr3 cells. SKOv3 cells, which lack the tumour suppressor protein Ras homolog member I, was found to have constitutively phosphorylated mitogen activated protein kinase and functionally increased Ras activity. SKOv3 cells further had low expression levels of PTEN. We thus confirm that the anti-proliferative effect of Herceptin in SKBr3 cells is due to recruitment of PTEN to the plasma membrane and conclude that Herceptin does not blunt phosphatidyl inositol 3 kinase-induced growth in cells with constitutive Ras activity. We further conclude that endocytic downregulation of ErbB2 does not contribute to Herceptin's antiproliferative effect.

Citing Articles

A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer.

Nami B, Wang Z Cells. 2024; 13(17.

PMID: 39273024 PMC: 11394428. DOI: 10.3390/cells13171452.


Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody-Drug Conjugate Therapies.

Major M, Nervig C, Gerland A, Owen S Pharmaceutics. 2024; 16(6).

PMID: 38931874 PMC: 11206718. DOI: 10.3390/pharmaceutics16060752.


EGFR trafficking: effect of dimerization, dynamics, and mutation.

Schultz D, Billadeau D, Jois S Front Oncol. 2023; 13:1258371.

PMID: 37752992 PMC: 10518470. DOI: 10.3389/fonc.2023.1258371.


Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer.

Yang M, Li Y, Kong L, Huang S, He L, Liu P J Clin Invest. 2023; 133(14).

PMID: 37463446 PMC: 10348774. DOI: 10.1172/JCI164428.


Influence of Folate-Targeted Gold Nanoparticles on Subcellular Localization and Distribution into Lysosomes.

Daniele R, Brazzale C, Arpac B, Tognetti F, Pesce C, Malfanti A Pharmaceutics. 2023; 15(3).

PMID: 36986724 PMC: 10053352. DOI: 10.3390/pharmaceutics15030864.